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The goal of asthma management is to achieve and
maintain control of symptoms.1 Although inhaled cortico-
steroids (ICSs) represent the cornerstone of asthma therapy,
the combination of a long-acting b2-agonist (LABA) with an
ICS is the treatment option advocated in patients whose
asthma is not controlled with low-dose ICS monotherapy.1
It is well recognized that ICS/LABA therapy can signiﬁcantly
improve asthma symptoms and control compared with
simply increasing a patient’s ICS dosage.2,3 Therapy with
an ICS/LABA combination via a single inhaler may offer
signiﬁcant beneﬁts over the use of separate inhalers,
facilitating patient adherence to both the ICS and LABA
components of the treatment regimen.4 6 Furthermore,
when ICSs and LABAs are administered as a single-aerosol
combination, they may interact synergistically at the
molecular level within the lung, enhancing their overall
pharmacological, and potentially therapeutic, effect.7
Cumulative evidence from many randomized controlled
trials demonstrates that single-inhaler ICS/LABA therapies
are highly effective in the management of asthma. When
these therapies ﬁrst became commercially available in the
1990s, it was widely thought that their use would change
the course of asthma management and signiﬁcantly improve
overall asthma control levels. Indeed, combination products
have contributed to better asthma outcomes compared
with ICSs alone, including a reduction in the number
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of mild and severe asthma exacerbations.8,9 However,
despite the fact that these therapies are available and are
recommended for use by international guidelines, asthma
control remains suboptimal for many patients. Although
the prevalence of asthma appears to have stabilized in
some European countries, a large proportion of patients
continue to experience the symptoms of poorly controlled
disease, even in regions that reportedly have good standards
of care for asthma.10 14 Therefore, morbidity associated
with uncontrolled asthma remains a signiﬁcant worldwide
health and economic problem, despite the availability of
several efﬁcacious management options.12,15 The burden
of disease accounts for approximately 15 million disability-
adjusted life-years lost per year worldwide. This is similar
to the global impact of diabetes or cirrhosis of the liver.12
It therefore appears that there is a discrepancy between the
efﬁcacy of ICS/LABA products in a clinical trial setting and
their effectiveness in real-world practice.16 This suggests
that there is scope for improving asthma management
options.
Although emphasis is often placed on the importance of
educating patients to encourage adherence to therapy,17,18
speciﬁc treatment attributes may also inﬂuence the
potential for patient acceptance of and adherence to
treatment regimens. For example, ICS/LABA therapies that
provide rapid bronchodilation are important to patients,19
with many indicating that they would like a maintenance
therapy that they can feel working soon after taking it.20 An
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ICS/LABA therapy with a fast onset of action may therefore
encourage patients to adhere to therapy;19 21 increased
adherence may contribute to improved asthma control.22
An additional ICS/LABA combination therapy has been
approved in Europe for the treatment of asthma when the
use of ICS/LABA therapy is appropriate (from step 3 of
the Global Initiative for Asthma guidelines). The product
brings together ﬂuticasone propionate (ﬂuticasone), a
potent ICS with a well-established efﬁcacy proﬁle,23 27
and formoterol fumarate (formoterol), the most rapid-
acting inhaled LABA currently available for the treatment
of asthma,28,29 in a single hydroﬂuoroalkane-based aerosol
(ﬂuticasone/formoterol; ﬂutiform®). Both ﬂuticasone and
formoterol are highly effective in treating asthma.23,27,30
The safety and efﬁcacy proﬁles of ﬂuticasone and formoterol
are well established, and the combined efﬁcacy of the
two components as a single-aerosol combination therapy
holds promise in terms of potential for real-world clinical
effectiveness.26,27,30,31
To evaluate the aspects of combination therapy con-
sidered important in terms of potential clinical beneﬁts,
Mundipharma International Limited sponsored a European
advisory meeting attended by 18 experts in respiratory
medicine. The meeting provided a platform for attendees
to explore current thinking on what characteristics of
an ICS/LABA treatment are important and to discuss
the ways in which the regulatory clinical trial data
for the product, ﬂuticasone/formoterol, and the well-
characterized pharmacological proﬁles of its individual ICS
and LABA components may translate into clinical beneﬁts
in practice. In order to share the meeting output with the
wider respiratory community, this supplement reviews some
of the data that formed the basis for the discussions at the
advisory meeting.
• David Price and Jean Bousquet32 provide an overview
of results from attitudinal research, which identiﬁes
ICS/LABA attributes considered to be important by
respiratory physicians across Europe.
• Michael Tamm and colleagues33 provide a review of the
pharmacological data that may be considered, in the
context of supporting clinical data, when looking to
identify the potential beneﬁts of speciﬁc ICSs and LABAs.
• Finally, Sanjeeva Dissanayake and colleagues34 provide a
review of the clinical data for ﬂuticasone/formoterol that
have been published to date.
This collection of review articles aims to provide an insight
into the potential for an additional ICS/LABA single-inhaler
therapy to expand the respiratory physician’s toolbox of
treatment approaches, with a view to helping to close
the gap between asthma control achieved in randomized
controlled trials and that still sought in clinical practice.
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